Novo Nordisk's shares dropped 17% after the company warned of declining sales and profits in 2026, following a pre-release of its outlook. The company is facing pressure from competition and has reduced prices for its GLP-1 drugs. Despite a challenging year in 2025, there are signs of demand for a new oral version of Wegovy. Leadership changes are also occurring, with David Moore leaving and Jamie Miller taking over. Teljes cikk (Euronews.com)